Balancing Scientific Innovation with Lived Experience: A Strategic Imperative in Pediatric Clinical Trials

Modern pediatric medicine has achieved extraordinary scientific progress. Survival rates for childhood cancers have improved dramatically. Gene therapies are redefining what is possible in ultra-rare diseases. Pediatric clinical trials increasingly incorporate biomarkers, precision diagnostics, decentralized components, and adaptive designs.

Yet alongside this progress lies a persistent gap.

While sponsors and investigators have optimized for survival endpoints and regulatory milestones, we have not consistently optimized for how trial participation is experienced, particularly when research is the only therapeutic option and outcomes are uncertain.

In pediatric trials, experience is not peripheral. It is clinically and operationally relevant.

A growing body of literature across pediatrics, palliative care, communication science, and patient-engaged research demonstrates that:

• Studies of pediatric intensive care unit (PICU) survivors demonstrate elevated rates of post-traumatic stress symptoms, anxiety, and depression months to years after discharge, even when physical recovery is good.^1-4
• Reduced autonomy, immobility, sleep disruption, and sensory deprivation are independently associated with pediatric delirium and long-term neuropsychological effects.^5-8
• Early, needs-based pediatric palliative care focused on quality of life rather than prognosis has been shown to improve symptom control, reduce psychological distress in both children and caregivers, and strengthen trust between families and care teams.^9-10

Regulators are increasingly recognizing this. The FDA's Patient-Focused Drug Development guidance emphasizes systematic incorporation of patient experience data into trial design and regulatory submissions.¹¹ ICH E6(R3) reinforces quality-by-design principles and proportionality of burden in clinical research.¹²

For sponsors, lived experience is not a soft variable. It influences recruitment feasibility, retention durability, protocol stability, and regulatory confidence. If pediatric research is to remain scientifically rigorous and ethically aligned with evolving regulatory expectations, it must balance innovation with lived experience.

The hidden variable in pediatric trials: Experience

Protocol development focuses on endpoints, powering, safety monitoring, and operational feasibility. On paper, designs are rational and compliant. Inside a pediatric hospital room, the variables shift.

Hospitalized children experience loss of autonomy, sleep disruption, and prolonged uncertainty. Parents of critically ill children report sustained anxiety, depression, and post-traumatic stress.^1-4 These factors influence decision-making capacity, trust in investigators, adherence, and willingness to remain in a study.

In rare disease and transplant settings, where many pediatric trials operate, the care environment itself becomes part of the treatment burden.

When trial experience is poorly aligned with developmental realities, sponsors encounter predictable consequences: slower recruitment, higher early withdrawal, increased protocol deviations, and greater site strain.

Ignoring experience introduces an uncontrolled variable into execution.

Psychological safety and clinical trial performance

Play, movement, humor, and autonomy are often viewed as secondary to medical necessity. Developmental and critical care literature suggest otherwise.

Reduced autonomy and prolonged confinement are associated with pediatric delirium and long-term psychological sequelae.^5-8 Post-traumatic stress symptoms in pediatric intensive care survivors can persist for years.^1-4

Evidence from pediatric therapeutic play and music-based interventions demonstrates reductions in anxiety, behavioral distress, and procedural pain during hospitalization and medical procedures.^13-17

Psychological safety improves cooperation, communication, and adherence.

In trial settings, this translates to:

• Participant retention
• Visit compliance
• Data completeness
• Reduced protocol deviations

Quality-by-design approaches call for early identification of risks that could affect participant safety or data integrity. Psychological safety directly intersects with both.

Psychological safety is not decorative. It is structural to trial performance.

Consent under duress

In pediatric rare disease trials, participation is often not elective. It may be the only available option.

Informed consent is defined as a process but frequently executed as documentation. Comprehension declines under stress, sleep deprivation, and emotional overwhelm. Even highly educated caregivers demonstrate limited retention of key risk information during acute decision windows.^18-21

If families do not fully understand the tradeoffs embedded in trial participation, the integrity of patient experience data is compromised.

For sponsors, this means:

• Consent must be revisited as prognosis evolves.
• Processing capacity shifts over time.
• "Key information" summaries are necessary but insufficient.
• A signed form does not ensure durable understanding.

Families who later realize they misunderstood implications are more likely to experience regret, conflict, or withdrawal. Longitudinal consent models are ethically sound and operationally protective.

Language as a trial variable

Clinician language influences trust, adherence, and long-term psychological outcomes. Terms such as "failed treatment" or "withdrawing care" shape interpretation and memory. Communication research shows families prefer direct, clear communication over euphemism, even in difficult contexts.

In pediatric research, language affects:

• Retention
• Conflict escalation
• Withdrawal decisions
• Post-trial sponsor perception

Regulators increasingly assess not only safety data, but how patient-reported outcomes and experience data were collected. Communication quality influences the reliability of those data.

Language is an intervention. Scientific rigor must extend to how investigators speak.

Caregiver burden and operational stability

Caring for a child with serious illness places substantial physical and psychological strain on caregivers. Research demonstrates strong associations between sustained caregiver burden and increased rates of depression, anxiety, sleep deprivation, impaired decision-making, and long-term health consequences.^24-27

In trials requiring frequent visits, complex monitoring, or travel, caregiver burden compounds.

Unmitigated strain can lead to missed visits, protocol deviations, and higher dropout risk.

Simple interventions—clear communication, anticipatory guidance, privacy, and emotional validation—are associated with improved caregiver coping and trust.^28-30

Reducing burden strengthens trial execution and improves family experience. Burden is measurable and should be incorporated into feasibility modeling.

When more intervention is not better

In investigational settings, the impulse to escalate is strong. Yet pediatric palliative research demonstrates that aggressive interventions near death often increase symptom burden without extending meaningful survival.

Early goals-of-care discussions correlate with lower caregiver distress and improved bereavement outcomes.

Trial frameworks should assume that some participants may experience life-limiting progression during enrollment. Communication plans and support structures should reflect that reality. Balancing quality of life with survival endpoints does not weaken innovation. It strengthens ethical credibility and long-term sponsor trust.

Why this matters to sponsors

Balancing scientific innovation with lived experience is strategic alignment with where regulation and trial quality standards are moving.

In pediatric trials, experience influences:

• Recruitment velocity
• Retention durability
• Amendment frequency
• Site burden
• Data completeness
• Regulatory trust

Sponsors that integrate patient experience upstream, consistent with PFDD principles and quality-by-design frameworks, reduce ethical risk and operational volatility. Trials are conducted in hospital rooms, under stress, with children whose developmental needs continue regardless of protocol demands.

Scientific excellence alone is no longer sufficient. Sustainable pediatric innovation requires systems that protect both data integrity and childhood.

A lived-experience perspective on pediatric trial design

This perspective is not theoretical for me. I began this work after my daughter Rona died from complications of treatment for a rare disease. Rona loved science. She also loved dance parties, pranks with saline flushes, and finding ways to remain a child inside a hospital room.

In the year we spent navigating pediatric medicine and research, I saw both the extraordinary power of scientific innovation and the unintended ways systems can erode childhood. I later founded Rona's FUN LAB in her honor, not to critique medicine, but to strengthen it.

Through that work, we developed the FUN LAB framework, which translates lived experience into six principles for pediatric care and research: Fun, Understanding, Nuance, Lighten, Ally, and Balance. The framework emphasizes protecting childhood, improving communication and informed consent, reducing caregiver burden, partnering with families, and balancing scientific progress with quality of life.

Balancing scientific innovation with lived experience is not sentiment. It is disciplined, regulator-aligned pediatric research.

Lindsey Wahlstrom, founder, Rona’s FUN LAB

References

1. Balluffi A, et al. Traumatic stress in parents of children admitted to the PICU. Pediatr Crit Care Med. 2004;5(6):547-553.
2. Rennick JE, Rashotte J. Psychological outcomes following PICU hospitalization. J Pediatr Psychol. 2009;34(5):410-423.
3. Abela KM, et al. Impact of pediatric critical illness on families. J Pediatr Nurs. 2020;51:21-31.
4. Bronner MB, et al. PTSD in parents after PICU treatment. J Pediatr Psychol. 2010;35(7):806-813.
5. Traube C, et al. Delirium in critically ill children. Crit Care Med. 2017;45(5):891-898.
6. Silver G, et al. Pediatric delirium recognition and management. Lancet Child Adolesc Health. 2018;2(2):134-142.
7. Schieveld JNM, et al. Pediatric delirium outcomes. Pediatrics. 2015;135(4):e1203-e1213.
8. Smith HAB, et al. Sleep disruption in pediatric intensive care. Crit Care. 2014;18(3):R132.
9. Wolfe J, et al. Symptoms and suffering at the end of life in children with cancer. JAMA. 2000;284(19):2469-2475.
10. Zimmermann C, et al. Early palliative care outcomes. Lancet. 2014;383(9930):1721-1730.
11. U.S. Food and Drug Administration. Patient-Focused Drug Development Guidance Series. https://www.fda.gov/drugs/development-approval-process-drugs/patient-focused-drug-development. Accessed March 4, 2026.
12. International Council for Harmonisation (ICH). ICH Harmonised Guideline E6(R3): Guideline for Good Clinical Practice. January 6, 2025. https://www.ich.org. Accessed March 4, 2026.
13. Godino-Iáñez MJ, et al. Play therapy as an intervention in hospitalized children. Healthcare. 2020;8(3):239.
14. Street RL Jr, et al. How does communication heal? Patient Educ Couns. 2009;74(3):295-301.
15. Hartling L, et al. Music to reduce pain and distress in pediatric emergency care. JAMA Pediatr. 2013;167(9):826-835.
16. Johnson AA, et al. Effects of music-based interventions in hospitalized children. J Pediatr Nurs. 2021;58:40-47.
17. da Silva RDM, et al. Therapeutic play for invasive procedures: systematic review. J Pediatr (Rio J). 2017;93(1):6-16.
18. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 8th ed. Oxford University Press; 2019.
19. Appelbaum PS, et al. Therapeutic misconception in clinical research. IRB. 1987;9(2):1-6.
20. Flory J, Emanuel E. Interventions to improve informed consent understanding. JAMA. 2004;292(13):1593-1601.
21. Nishimura A, et al. Improving understanding in the informed consent process. BMC Med Ethics. 2013;14:28.
22. Mack JW, et al. Prognostic communication with parents of children with cancer. J Clin Oncol. 2006;24(33):5265-5270.
23. Bluebond-Langner M, et al. Parent-child communication in serious illness. J Clin Oncol. 2007;25(17):2414-2419.
24. Raina P, et al. Health and well-being of caregivers of children with disabilities. Pediatrics. 2005;115(2 Suppl):e1-e13.
25. Given BA, et al. Support for caregivers of cancer patients. CA Cancer J Clin. 2011;61(1):50-63.
26. Streisand R, et al. Caregiver stress and pediatric treatment adherence. J Pediatr Psychol. 2005;30(6):513-521.
27. Kuster PA, Badr LK. Mental health of mothers caring for medically complex children. Issues Ment Health Nurs. 2006;27(1):75-91.
28. Curtis JR, White DB. Evidence-based ICU family conferences. Chest. 2008;134(4):835-843.
29. Lautrette A, et al. Communication strategies for ICU families. N Engl J Med. 2007;356(5):469-478.
30. Figley CR. Compassion fatigue. J Trauma Stress. 1995;8(2):293-300.
31. Wright AA, et al. Associations between aggressive end-of-life care and bereavement outcomes. JAMA. 2008;300(14):1665-1673.